The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Related to this article
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
Advertisement
Advertisement
Trending on Urology Times
1
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
Altaviva™ Tibial Implant Is Reshaping UUI Therapy
4
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
5